Search company, investor...

Ausio Pharmaceuticals


Incubator/Accelerator | Alive

About Ausio Pharmaceuticals

Ausio Pharmaceuticals is a company focused on the clinical development of S-Equol for major medical needs.

Headquarters Location

1776 Mentor Avenue

Cincinnati, Ohio, 45212,

United States


Missing: Ausio Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ausio Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Ausio Pharmaceuticals Patents

Ausio Pharmaceuticals has filed 4 patents.

patents chart

Application Date

Grant Date


Related Topics




Synthetic estrogens, Alzheimer's disease, Phenols, Small nuclear RNA, Amines


Application Date


Grant Date



Related Topics

Synthetic estrogens, Alzheimer's disease, Phenols, Small nuclear RNA, Amines



Latest Ausio Pharmaceuticals News

Estrogen Receptor Beta Partial Agonist Pipeline Insights, 2018 Report Featuring Ausio Pharmaceuticals, AstraZeneca, ENDECE, ACADIA Pharmaceuticals & Eli Lilly -

Dec 19, 2018

Estrogen Receptor Beta Partial Agonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Estrogen Receptor Beta Partial Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Descriptive coverage of pipeline development activities for Estrogen Receptor Beta Partial Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. The report assesses the active Estrogen Receptor Beta Partial Agonist pipeline products by developmental stage, product type, molecule type, and administration route. Key Topics Covered:

Ausio Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Ausio Pharmaceuticals's headquarters?

    Ausio Pharmaceuticals's headquarters is located at 1776 Mentor Avenue, Cincinnati.

  • What is Ausio Pharmaceuticals's latest funding round?

    Ausio Pharmaceuticals's latest funding round is Incubator/Accelerator.

  • Who are the investors of Ausio Pharmaceuticals?

    Investors of Ausio Pharmaceuticals include Hamilton County Business Center.

  • Who are Ausio Pharmaceuticals's competitors?

    Competitors of Ausio Pharmaceuticals include Deciphera Pharmaceuticals, VentiRx Pharmaceuticals, Reata Pharmaceuticals, Bellicum Pharmaceuticals, Omthera Pharmaceuticals and 12 more.

Compare Ausio Pharmaceuticals to Competitors

Ribozyme Pharmaceuticals

Ribozyme Pharmaceuticals offers RNA-based pharmaceuticals for human disease

KeyNeurotek Pharmaceuticals

KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.

Alinea Pharmaceuticals

Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders

Bluefish Pharmaceuticals

Bluefish Pharmaceuticals offers a range of quality pharmaceuticals at prices that as many as possible will be able to afford.

Greystone Pharmaceuticals

Greystone Pharmaceuticals is a healthcare company focused on wound technologies.

Mimetogen Pharmaceuticals

Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.